Literature DB >> 1478536

Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience.

H H Brackmann1, H J Eickhoff, J Oldenburg, U Hammerstein.   

Abstract

Between 1978 and 1989, a controlled study was performed on children and adolescents suffering from severe haemophilia A. Special attention was given to long-term therapy adjusted to the patients' requirements. The clinical and the X-ray scores of the Orthopaedic Advisory Committee of the World Haemophilia Society were used to assess the orthopaedic findings. The present investigation is a 12-year follow-up study of 90 patients affected with severe forms of haemophilia A. All knee and ankle joints of the patients were evaluated. After 12 years, the clinical scores remained unchanged or had been improved (knees 94%, X-ray score 97, ankles 86, X-ray score 88).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1478536     DOI: 10.1159/000216332

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  8 in total

1.  Need for Prophylactic Treatment in Adult Haemophilia A Patients.

Authors:  Berthold Siegmund; Heinrich Richter; Hartmut Pollmann
Journal:  Transfus Med Hemother       Date:  2009-07-10       Impact factor: 3.747

Review 2.  Secondary prophylaxis in adolescent and adult haemophiliacs.

Authors:  Annarita Tagliaferri; Caterina Di Perna; Gianna Franca Rivolta
Journal:  Blood Transfus       Date:  2008-09       Impact factor: 3.443

3.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 4.  Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.

Authors:  Omotola O Olasupo; Megan S Lowe; Ashma Krishan; Peter Collins; Alfonso Iorio; Davide Matino
Journal:  Cochrane Database Syst Rev       Date:  2021-08-18

5.  Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.

Authors: 
Journal:  CMAJ       Date:  1995-07-15       Impact factor: 8.262

6.  Treatment of hemophilia: a review of current advances and ongoing issues.

Authors:  Antonio Coppola; Mirko Di Capua; Matteo Nicola Dario Di Minno; Mariagiovanna Di Palo; Emiliana Marrone; Paola Ieranò; Claudia Arturo; Antonella Tufano; Anna Maria Cerbone
Journal:  J Blood Med       Date:  2010-08-30

7.  First analysis of 10-year trends in national factor concentrates usage in haemophilia: data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System.

Authors:  A N Traore; A K C Chan; K E Webert; N Heddle; B Ritchie; J St-Louis; J Teitel; D Lillicrap; A Iorio; I Walker
Journal:  Haemophilia       Date:  2014-07       Impact factor: 4.287

8.  Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand.

Authors:  J Oldenburg; R Zimmermann; O Katsarou; G Theodossiades; E Zanon; B Niemann; E Kellermann; B Lundin
Journal:  Haemophilia       Date:  2014-12-02       Impact factor: 4.263

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.